Rochea headquarters, multinational pharmaceutical industry on December 27, 2021 in Madrid, Spain.
Cristina Arias | Lid | Getty Images
Swiss pharmaceutical giant Roche said Wednesday that he had achieved a job worth up to $ 5.3 billion for the development of Danish biotechnics Zealand’s farmCandidate for Obesity Medicines, as two companies seek to compete on the growing weight loss medication market.
The agreement will see two companies participating in development and co-commercialize Petrelintide, Zealand Pharma Analog Amilin As an independent therapy, as well as a combination of fixed dose with Roche’s Incretin property of CT-388.
According to the Agreement, Zeland Pharma will receive a pre -payment of cash payments of $ 1.65 billion, with the potential of a turning point to pay a total of up to $ 5.3 billion, depending on stages of 3 trials and sales development, Roche said in a statement.
Zealand Pharma sections jumped 29% shortly after the announcement and 23% were traded for 10: 5- 5- Am in London, while Roche added 4.6%.
Stocks Diva for Obesity Medicines Novo NordiskIn the meantime, he slid 3.9% during the session on Wednesday as Eli Lilly immersed 1.5% in the store before the market.
Executive Director Zealand Pharma and President Adam Stoensberg told CNBC that the agreement showed that he was a strong obligation of two companies in the future in the obesity space. “
“Roche assured us that they had ambition to take the lead in this therapeutic space,” he told CNBC via a video call on Wednesday.
Danish biotechnology has long pointed out to the analogues of Amilin as “Next generation” weight loss treatment. They seem to mimic a hormone that is a coating with insulin in the pancreas to increase the satiety. This is different from the agonist GLP-1, which mimic engine hormones produced in the intestines for suppression of appetite and regulation of blood sugar.
“Unlike GLP-1, which makes people lose their appetite, Petrelintide can help people feel more full more faster,” Steensberg said.
